Vall D'hebron Institut De Recerca — Clinical Trial Site

127 Registered trials

47 Currently recruiting

Organisation

Vall D'hebron Institut De Recerca

Location

Barcelona, Spain

Identifier

ORG-100008455

Address

Passeig De La Vall D'hebron 119-129, 08035, Spain

Departments

3000: Hematología
Alergologia
Alergology
Allergologia
Cap de secció. Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria
Department of Medicine
Dermatology
Gynaecologic cancer
Gynecologic Oncology
Hematology
Hepathology
Hospital Vall Hebron
Infectious diseases
Infectious Diseases and immunodeficiencies
Infectious Pathology and Immunodeficiencies Unit pediatric
Instituto de Investigación Germans Trias i Pujol (IGTP)
Internal medicine
Jefe de Sección Servicio de Oncología y Hem. Ped. Vall d’Hebron Barcelona Hosp. Campus
Medical Oncology
Medical Oncology Department
N/A
NA
Nephrology
Nephrology and Transplantation
Neumología
Neumology
Neurologia
Neurology
Neurophysiology Department - Sleep Unit
Nuclear Medicine
Oncología
Oncologia Medica
Oncology
Oncology - Phase I Unit
Oncology (VHIO)
Oncology-Genitourinary
Ophthalmology
Paediatric Onco-Haematology
Pediartic Oncology-Hematology
Pediatric hematology and oncology.
Pediatric in Oncology and Hematology
Pediatric Oncology and Hematology
Pediatrics
Retina
Rheumatology
Rhumatology
Servei de Cardiologia
Servicio de Hematologia
Servicio de Neumología
Servicio de Oncología
Servicio de Oncología Médica
Servicio de Oncología y Hematología
Servicio de Oncología y Hematología Pediátricas
Servicio Enfermedades Infecciosas.
Servicio Neumología
Unidad de Neuroimmunología Clínica
Unit of Inherited Metabolic Disorders and Rare Diseases
Urology

Clinical trials at this site (127)

Search interface

AMAZE 3: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea… Recruiting

2024-520442-36-00 Overweight or obesity, and obstructive sleep apnoea not 5 2026-04-30
FINE-START; A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the eff… Recruiting

2025-523075-32-00 chronic kidney disease 5 2026-03-09
Inhibiting BCL-2 at the start of HIV treatment to reduce the HIV reservoir in people living with HIV Recruiting

2025-521841-26-00 HIV-1 infection 9 2026-02-20
To Study the Effect of Inavolisib in Combination with Fulvestrant in Participants with Breast Cancer Recruiting

2025-522805-39-00 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalyti 4 2026-02-06
STATIN-PRE trial Recruiting

2024-519853-12-00 intrauterine growth restriction 5 2026-01-14
Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) Recruiting

2024-519261-21-00 Desmoplastic small round cell tumor 4 2025-11-21
A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting

2023-509175-16-00 Sickle cell disease 5 2025-10-14
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Hereditary Angioedema 5 2025-03-28
Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1 Recruiting

2023-509748-89-00 Facioscapulohumeral muscular dystrophy (FSHD) 7 2025-02-19
A research study looking at long-term treatment with etavopivat in people with sickle cell disease or thalassaemia Recruiting

2024-510805-27-00 Sickle Cell Disease and Thalassaemia 5 2025-01-09
Respiratory rehabilitation in patients with ILD Recruiting

2024-519541-30-00 ILD 5 2024-11-27
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting

2023-504898-20-00 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iod 4 2024-07-30
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting

2022-501697-19-01 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5 2024-06-18
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting

2023-508808-38-00 Solid tumors 1 2024-05-29
Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas Recruiting

2023-509215-81-00 Adult and young adult patients with diagnosis of advanc 4 2024-05-22
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in pa… Recruiting

2023-505791-30-01 Diabetic Retinopathy 10 2024-04-17
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Recruiting

2023-508058-24-01 LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLOREC 1 2024-04-05
FOENIX-CCA4 Recruiting

2023-503665-39-00 Advanced cholangiocarcinoma 4 2023-11-14
An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting

2023-504973-19-01 early-stage, intermediate-risk cervical cancer 5 2023-09-06
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine… Recruiting

2023-506818-45-00 Solid tumors that have a high incidence of Homologous R 7 2022-12-13
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination … Recruiting

2024-514746-36-00 Selected tumor indications that are known to express FA 1 2022-10-20
A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors Recruiting

2023-503651-10-00 Male and female participants ≥ 18 years of age with adv 7 2022-05-17